Voyager’s VY1706 Gene Therapy Shows Up to 64% Tau Reduction—Alzheimer’s Clinical Trial Slated for Late 2026
Market Chameleon (Thu, 14-May 10:44 AM)
Voyager’s Clinical Pipeline Expands Amid Strong Cash Position and Strategic Partnerships
Market Chameleon (Tue, 10-Mar 11:16 AM)
